According to a new study published online 28 Feb 2022 (Centio et al., “Inhibition of oxidized nucleotide sanitation by TH1579 and conventional chemotherapy cooperatively enhance oxidative DNA-damage and survival in AML”, Mol Cancer Ther, doi: 10.1158/1535-7163.MCT-21-0185. Online ahead of print), OXC-101 (TH1579, karonudib) can inhibit AML progression as monotherapy but also boost standard chemotherapy response in AML pre-clinical models.
AML is an aggressive blood cancer with estimated 25% 5-year survival, mainly due to primary resistance or relapse towards standard therapeutic regimens. OXC-101 (karonudib, TH1579) has previously been shown to be effective in various AML pre-clinical models (Sanjiv et al., Cancer Research 2021). In the newly accepted article by Centio et al., this is further confirmed and synergistic effects between OXC-101 and standard chemotherapy for AML (the anthracycline doxorubicin) were observed.
“We are very pleased with these study results which clearly support future clinical studies combining standard chemotherapy for AML with OXC-101 to validate the promising synergistic effects” says Ulrika Warpman Berglund, CEO of Oxcia.
OXC-101 has a unique mechanism of action that fights cancer by utilizing the cancer’s inherently high levels of oxidative DNA damage and oxidative stress. OXC-101 induces cancer-specific oxidative stress and oxidative DNA damage and prevents the cancer cell from growing. The result is that the cancer cell dies. Healthy cells are only marginally affected, which lays the foundation for OXC-101 good tolerability.
OXC-101 is being investigated in two ongoing clinical phase 1 studies, one in advanced blood cancer and one in advanced solid tumors. They are planned to be finalized during 2022.
For further information please contact:
Ulrika Warpman Berglund, CEO
Phone: +46 (0) 73 270 96 05
Briefly about Oxcia
Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR – the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two DDR drug candidates, both with the potential to become first-in-class drugs. OXC-101 (Karonudib, TH1579) is being investigated in two ongoing clinical phase 1 studies, one in advanced solid tumors and one in hematological cancers. OXC-201 (TH5487) is developed against inflammatory and fibrosis-related diseases, such as pulmonary fibrosis, and is in the preclinical phase.
More information about Oxcia is available at www.oxcia.com